Get the Stockscreener App
10.19
3.77%
0.37
Mind Medicine Inc stock is traded at $10.19, with a volume of 1.74M.
It is up +3.77% in the last 24 hours and up +5.71% over the past month.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
See More
Previous Close:
$9.82
Open:
$9.83
24h Volume:
1.74M
Relative Volume:
1.42
Market Cap:
$775.34M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-4.1592
EPS:
-2.45
Net Cash Flow:
$-64.37M
1W Performance:
+6.04%
1M Performance:
+5.71%
6M Performance:
+33.55%
1Y Performance:
+70.54%
1-Day Range:
$9.795
$10.35
1-Week Range:
$9.11
$10.35
52-Week Range:
$4.70
$10.49
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
10.19 | 741.86M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
H.C. Wainwright Reiterates Buy Rating for Mind Medicine with $55 Price Target - AInvest
Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets - microdose.buzz
Is Mind Medicine (MindMed) Inc. Forming a Consolidation BaseTreasury Yields & Breakout Confirmation Trade Signals - newsimpact.co.kr
Mind Medicine (MindMed) Inc. Facing Inflection Point in Trend Analysis2025 Valuation Update & Momentum Based Trading Signals - 선데이타임즈
Mind Medicine (MindMed) Inc. Crosses 200 Day MA — Signal or NoiseWeekly Gains Summary & Detailed Earnings Play Alerts - 선데이타임즈
RSI Crosses Above 30 for Mind Medicine (MindMed) Inc. — Reversal in SightJuly 2025 News Drivers & Weekly Breakout Watchlists - 선데이타임즈
1 Reason to Buy MindMed (MNMD) - AOL.com
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today - MSN
MindMed Announces New Employee Inducement Grants - Business Wire
MindMed (MNMD) Q2 2025 Earnings Call Transcript - AOL.com
MindMed Reports Strong Q2 2025 Results - The Motley Fool
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) large institutional owners must be happy as stock continues to impress, up 17% over the past week - simplywall.st
Mind Medicine (MindMed) (NASDAQ:MNMD) Earns Outperform Rating from Analysts at Oppenheimer - MarketBeat
Using RSI to spot recovery in Mind Medicine (MindMed) Inc.Weekly Breakout Forecast with Entry Zones - Newser
What makes Mind Medicine (MindMed) Inc. stock price move sharplyFree Trade Ready Stock Watch for Short Term - Newser
MindMed Reports Strong Phase 3 Trial Progress and Leadership Appointment - The Globe and Mail
Pattern recognition hints at Mind Medicine (MindMed) Inc. upsideAlpha Generation Strategy with Low Volatility - Newser
Roth Capital Issues Pessimistic Outlook for MNMD Earnings - Defense World
What MACD signals say about Mind Medicine (MindMed) Inc.AI-Based Reversal Point Prediction Signal - Newser
What is HC Wainwright’s Forecast for MNMD FY2028 Earnings? - Defense World
Oppenheimer Initiates Coverage on Mind Medicine (MindMed) (NASDAQ:MNMD) - Defense World
Is Mind Medicine stock a buy? - Cantech Letter
Mind Medicine upgraded at Oppenheimer on lead asset - MSN
A Quick Look at Today's Ratings for Mind Medicine(MNMD.US), With a Forecast Between $18 to $55 - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM) - The Globe and Mail
MindMed Bets Big On Psychedelic Therapies With Cash To Spare - Finimize
Mind Medicine stock upgraded at Oppenheimer (MNMD:NASDAQ) - Seeking Alpha
Mind Medicine's Promising Pipeline and Financial Stability Drive Buy Rating - AInvest
Mind Medicine resumed with an Outperform at Oppenheimer - TipRanks
Mind Medicine’s Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
Mind Medicine (MNMD) Gains Positive Outlook with Oppenheimer's O - GuruFocus
Mind Medicine (MindMed)’s (MNMD) “Buy” Rating Reiterated at Chardan Capital - Defense World
What are the latest earnings results for Mind Medicine (MindMed) Inc.Invest confidently with advanced analysis tools - Jammu Links News
Why is Mind Medicine (MindMed) Inc. stock attracting strong analyst attentionFree Trading Psychology Coaching - Jammu Links News
How does Mind Medicine (MindMed) Inc. compare to its industry peersGet timely alerts on market opportunities - Jammu Links News
What is the dividend policy of Mind Medicine (MindMed) Inc. stockOutstanding capital returns - Jammu Links News
What analysts say about Mind Medicine (MindMed) Inc. stockAccelerate your capital gains today - Jammu Links News
Is it the right time to buy Mind Medicine (MindMed) Inc. stockHigh-yield portfolio picks - Jammu Links News
How does Mind Medicine (MindMed) Inc. generate profit in a changing economyAchieve rapid financial growth with smart picks - Jammu Links News
When is Mind Medicine (MindMed) Inc. stock expected to show significant growthAchieve breakthrough investment performance - Jammu Links News
How volatile is Mind Medicine (MindMed) Inc. stock compared to the marketAI Powered Signals For Consistent Profits - jammulinksnews.com
MindMed (MNMD) Q2 Net Loss Jumps 625% - The Globe and Mail
MindMed Reports Strong Q2 2025 Financial Results - The Globe and Mail
Unraveling the Sharp Drop in Mind Medicine (MNMD.O): A Technical and Order-Flow Deep Dive - AInvest
Mind Medicine Inc's Q2 2025 Earnings Call Highlights: Strong Financial Position and Strategic Advancements in MM-120 ODT Trials - AInvest
Earnings call transcript: MindMed Q2 2025 reveals cash runway into 2027 - Investing.com Canada
Mind Medicine (MindMed) Q2 2025 Earnings Call Transcript - MarketBeat
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mind Medicine Inc Stock (MNMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Karlin Daniel | Chief Medical Officer |
Jun 25 '25 |
Sale |
6.80 |
7,848 |
53,366 |
438,329 |
| Barrow Robert | Chief Executive Officer |
Jun 25 '25 |
Sale |
6.80 |
26,491 |
180,139 |
830,065 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):